Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors ; volume:23 ; number:1 ; day:12 ; month:7 ; year:2023 ; pages:1-9 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (12.7.2023), 1-9, 12.2023
- Urheber
-
Quee, F. A.
Hogema, B. M.
Slot, E.
Kruijer, S.
Molier, M.
Hurk, K. van den
Zaaijer, H. L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08448-w
- URN
-
urn:nbn:de:101:1-2023101808490028269052
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Quee, F. A.
- Hogema, B. M.
- Slot, E.
- Kruijer, S.
- Molier, M.
- Hurk, K. van den
- Zaaijer, H. L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
Antibody titers in turkeys increase after multiple booster vaccinations with an attenuated Salmonella live vaccine
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Vaccinations-Anstalt
Vaccinations-Atteste
Meningococcal Vaccinations
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
Antibody titers in turkeys increase after multiple booster vaccinations with an attenuated Salmonella live vaccine
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Vaccinations-Anstalt
Vaccinations-Atteste
Meningococcal Vaccinations
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
Antibody titers in turkeys increase after multiple booster vaccinations with an attenuated Salmonella live vaccine
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Vaccinations-Anstalt
Vaccinations-Atteste
Meningococcal Vaccinations
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022